TechGuru,-
How many patients we will have in our combo will depend of education we will give to doctors and our patients.

Combo will be approve for MDR-3 and MDR-2 will limitation to other drugs .
Because almost every patient has some side effects with HAART , they all really have limitations , so this is very easy for doctors to prove...

We expect to see over 180,000 patients in USA only , in 2020 with MDR-2 who are R-5 HIV strain.
The only competition here is Maraviroc with it severe side effects , possibilities of resistance and efficacy of 45% , compare to 81% with 350 mg dose with Leronlimab , and not one severe side effect so far ..

If I will take care of these over 180,000 patients , knowing what I know about Leronlimab and HAART ,
all my patients will be on Leronlimab ,first to prevent development of MDR-3 , when patients are very sick already , I will also stop all HAART with the most side effects , like tenofovir which we know now is very suspicious of producing NASH , and to diminished possibilities of other problems from those drugs.

MDR-3 in USA we expect about 10,000 R-5 strain in 2020.

Competition here is also Maraviroc with 45% efficacy
and
Ibalizumab , every 2 weeks IV infusion , with some side effects and efficacy of 43%. , compare to 81% with Leronlimab.


So we could see that how many patients we will have will depend how educated are doctors and patients...
And as a rule HIV positive patients are one of the most educated group of patients.



All IMO as always.